Esperion Therapeutics, Inc. IPO Research Information

Esperion Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Esperion Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Esperion Therapeutics, Inc.	ESPR - NASDAQ	$13.00-$15.00	$14.00	$17.00	5 million	6/26/2013
Underwriter(s): Credit Suisse, Citigroup
Co-Manager(s): JMP Securities, Stifel
Industry: Health Care
Filing(s): Filed 2013-05-14

Esperion Therapeutics, Inc. Quote & Chart - Click for current quote - ESPR

About Esperion Therapeutics, Inc. (adapted from Esperion Therapeutics, Inc. prospectus):
They are a biopharmaceutical company focused on the research, development and commercialization of therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol (LDL-C) and other cardiometabolic risk factors.

This description is adapted from Esperion ESPR prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as Esperion ESPR "ESPR" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.